Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.102    
    

EXECUTION COPY  

ESCROW AGREEMENT  

        This Escrow Agreement (this "Agreement") is made and entered into as of September 20, 2007, by and among
Advanced Cell Technology, Inc., a Delaware corporation (the "Buyer"), Michael O'Malley (the "Stockholder
Representative"), and Mellon Trust of New England, N.A., a national banking association, as escrow agent (the "Escrow Agent").
The Stockholder Representative and the Buyer are referred to herein collectively as the "Escrow Parties." Capitalized terms used but not defined herein
shall have the meanings given to them in the Merger Agreement (as defined below). 

Introduction  

        The Buyer, ACT Acquisition Sub, Inc. (the "Buyer Subsidiary"), Mytogen, Inc., a Delaware corporation
(the "Company"), all of the Company's stockholders and all of the holders of Stock Rights (the
"Stockholders") and the Stockholders Representative have entered into an Agreement and Plan of Merger, dated as of July 31, 2007 (the
"Merger Agreement"), pursuant to which the Buyer Subsidiary will be merged with and into the Company, the separate corporate existence of Buyer
Subsidiary shall cease and the Company shall continue as the surviving corporation and shall continue as a wholly-owned subsidiary of the Buyer. Pursuant to Section 4.3(a) of the Merger
Agreement, the Buyer shall deliver the Escrow Shares to the Escrow Agent as security for the indemnification obligations of the Stockholders under Article 15 of the Merger Agreement. The Escrow
Parties desire to appoint the Escrow Agent as the escrow agent for the Escrow Shares and the parties hereto wish to specify their respective rights and obligations with respect to the Escrow Shares
under this Agreement. 

        NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 

        1.    Appointment of Agent.    The Escrow Parties hereby appoint Mellon Trust of New England, N.A. as Escrow Agent
under this Agreement, and the Escrow Agent hereby accepts such appointment. The Stockholder Representative represents and warrants to the Escrow Agent that it has been duly appointed as the
Stockholder Representative and has the power and authority (a) to enter into this Agreement, (b) perform the obligations of the Stockholder Representative under this Agreement and
(c) take any and all actions and make any decisions required or permitted to be made by the Stockholder Representative under this Agreement. 

        2.    Deposit of Escrow Shares.    

         (a)   On the date hereof, the Buyer shall deliver to the Escrow Agent, in accordance with Section 4.3(a) of the Merger Agreement and the
terms
and conditions hereof, certificates representing 1,209,678 shares of Buyer Common Stock (the "Escrow
Shares") issued pursuant to the Merger Agreement and registered in the name of the Escrow Agent for the benefit of the Stockholders in the relative amounts set forth on  Schedule I hereto (the "Initial Escrow Shares"). Any shares of Buyer Common Stock that result
from any share dividend, reclassification, stock split, subdivision or combination of shares, recapitalization, merger or other events made with respect to the Escrow Shares held in escrow under this
Agreement (the "Additional Shares") shall be delivered to the Escrow Agent and shall be held by the Escrow Agent in accordance with this Agreement.
Unless otherwise indicated, as used in this Agreement, the term "Escrow Shares" includes both the Initial Escrow Shares and any Additional Shares. The
Escrow Shares shall be held hereunder by the Escrow Agent as security for the indemnification obligations of the Stockholders under Section 15 of the Merger Agreement, as more specifically set
forth therein, to the Indemnified Parties. 

 

         (b)   The Escrow Agent shall hold the Escrow Shares at Mellon Trust of New England, N.A. in accordance with the terms and conditions of this
Agreement
until all of the Escrow Shares have been released pursuant to the terms and conditions of this Agreement. 

        (c)   Any cash dividends, dividends payable in property or other distributions of any kind (except for Additional Shares) made in respect of the
Escrow
Shares shall be distributed currently by the Buyer to the Stockholders on a pro rata basis, provided that no distribution shall be made to a Stockholder
until such Stockholder has satisfied the conditions set forth in Section 5.2 of the Merger Agreement. Each Stockholder shall have the right to vote the Escrow Shares held in escrow for the
account of such Stockholder so long as such Escrow Shares are held in escrow, provided that such Stockholder has satisfied the conditions set forth in
Section 5.2 of the Merger Agreement. The Stockholder Representative and the Escrow Agent, but only as directed in writing by the Stockholder Representative, shall take all steps necessary to
allow the exercise of such voting rights. In the absence of written directions from the Stockholder Representative, the Escrow Agent shall not vote any of the Escrow Shares. While the Escrow Shares
remain in the name of the Escrow Agent and in its possession pursuant to this Escrow Agreement, the Stockholders that have satisfied the conditions set forth in Section 5.2 of the Merger
Agreement shall retain and shall be able to exercise all other incidents of ownership of the Escrow Shares that are not inconsistent with the terms and conditions hereof. 

        (d)   None of the Escrow Shares or any beneficial interest therein may be pledged, sold, assigned or transferred, including by operation of law,
by a
Stockholder, or may be taken or reached by any legal or equitable process in satisfaction of any debt or other liability of a Stockholder, prior to the delivery of the Escrow Shares by the Escrow
Agent or the Buyer to such Stockholder pursuant to this Escrow Agreement; provided, however, in the
event of any attachment or attempted attachment of the Escrow Shares, the Escrow Agent shall provide written notice to the Buyer and the Stockholder Representative of such attachment or attempted
attachment and shall act with respect thereto upon their joint written instruction; provided however, that the Escrow Agent shall in all cases be
entitled to act in accordance with any Court Order (as defined below) or the order of any other governmental authority without incurring any liability to any of the parties hereto. 

         (e)   The Escrow Agent is hereby granted the power to effect any transfer of the Escrow Shares provided for in this Escrow Agreement. With
respect to
the distribution of any Escrow Shares pursuant to this Agreement, the Escrow Agent and the Buyer will take such action as may be necessary (i) to cause appropriate certificates to be issued and
delivered to the Stockholders or the Buyer, as the case may be, and (ii) to the extent necessary, if not all Escrow Shares are distributed, to cause appropriate certificates to be issued and
delivered to the Escrow Agent representing the number of Escrow Shares remaining after such distribution. In connection therewith, the Escrow Agent shall deliver to the Buyer certificates representing
the appropriate number of Escrow Shares to be released to the Buyer and/or the Stockholders and the Buyer shall reissue in the name(s) of the intended recipients and deliver to the Escrow Agent
certificates for such number of Escrow Shares that are then to be distributed to the Buyer and/or the Stockholders pursuant to this Agreement, and the Buyer shall reissue in the name of the Escrow
Agent as escrow agent for the benefit of the Stockholders, and deliver to the Escrow Agent, certificates for such number of Escrow Shares, if any, that are to be retained by the Escrow Agent. 

        3.    Disposition of Escrow Shares.    

         (a)   If, at any time on or prior to the earlier of (i) eighteen (18) months following the date hereof and (ii) the date of the
final release of the last of the Escrow Shares pursuant to the terms and subject to the conditions hereof (the "Escrow Termination Date"), the Buyer
believes that any Indemnified Party is entitled to indemnification from the Stockholders pursuant to Article 15 of the Merger Agreement, the Buyer shall deliver to the Escrow Agent and the
Stockholder 

2

 

Representative,
prior to the Escrow Termination Date, a written notice (a "Claim Notice") describing in reasonable detail the facts constituting the
basis for such indemnification claim (a "Claim") and the number, or an estimate thereof, of Escrow Shares sought therefore (a
"Claimed Amount"). Notwithstanding the then current market price of the shares of Buyer Common Stock, for purposes of this Agreement, each Escrow Share
shall be deemed to have a value of $0.62. From the date that a Claim Notice is received by the Escrow Agent (notice of such date shall be given by the Escrow Agent to the Stockholder Representative
upon request therefor), the Stockholder Representative shall have thirty (30) days (the "Notice Period") to deliver to the Escrow Agent, with
copies to the Buyer, contrary instructions disputing in good faith the Claim Notice and describing generally why the Buyer is not entitled to the Claimed Amount and the portion of the Claimed Amount
being disputed (a "Dispute Notice"). If the Escrow Agent does not receive a Dispute Notice prior to 5:00 p.m. (Eastern Time) on the last day of
the Notice Period, the Escrow Agent shall, within two (2) business days, release the Claimed Amount (but, in any event, no more than the total number of Escrow Shares) in accordance with the
disbursement instructions contained in the Claim Notice. If the Escrow Agent receives a Dispute Notice prior to 5:00 p.m. (Eastern Time) on the last day of the Notice Period, the Escrow Agent
shall continue to hold the Claimed Amount until (x) it shall receive Joint Written Instructions (as defined below) as to the disposition of such sum or (y) it shall be otherwise ordered
by a final, non-appealable order or decree of a court of competent jurisdiction, a copy of which shall be certified as such and provided to each party in accordance with the provision of
Section 9 hereof (a "Court Order"). The Escrow Agent shall have no duty or obligation to determine whether a Court Order complies with the
requirements of subclause (y) of this Section 3(a). In the event of any release of Escrow Shares under this Section 3(a), in lieu of releasing any fractional Escrow Shares, any
fraction of a released Escrow Share that would otherwise be released shall be rounded to the nearest whole Escrow Share, to the extent of the Escrow Shares. 

         (b)   Notwithstanding anything to the contrary contained in this Agreement, if the Escrow Agent receives written instructions from all of the
Escrow
Parties, or their respective successors or assigns, substantially in the form of Exhibit A, as to the disbursement of some or all of the Escrow
Shares ("Joint Written Instructions"), the Escrow Agent shall disburse the Escrow Shares (or any portion thereof) pursuant to such Joint Written
Instructions. 

         (c)   Promptly following the Escrow Termination Date, but in any event not later than three (3) business days after the Escrow Termination
Date,
the Escrow Agent shall commence such actions as may be required to distribute or cause to be distributed to each Stockholder such Stockholder's pro rata portion of the Escrow Shares (based upon the
ratio of (i) the number of Consideration Shares received by each such Stockholder at the Closing, to (ii) the total number of Consideration Shares issued to all of the Stockholders at
the Closing) less that number of shares as would (valued as provided in Section 3(a) above) equal the amount of any Claimed Amounts required to
be retained as of the Escrow Termination Date pursuant to Section 3(a) above. In lieu of releasing any fractional Escrow Shares under this Section 3(c), any fraction of a released Escrow
Share that would otherwise be released shall be rounded to the nearest whole Escrow Share, to the extent of the Escrow Shares. Notwithstanding anything herein to the contrary, no Escrow Shares shall
be released to any Stockholders that have not satisfied the conditions set forth in Section 5.2 of the Merger Agreement, provided that, prior to
such release, the Buyer shall have given written notice to such effect to the Escrow Agent with a copy to the Stockholder Representative. If the Escrow Agent receives written notice from the Buyer
that a Stockholder has not satisfied the conditions set forth in Section 5.2 of the Merger Agreement, any Escrow Shares that would otherwise be released to such Stockholder shall instead be
released to the Buyer to be held subject to Section 5.2 of the Merger Agreement and otherwise in accordance with applicable law. If the Escrow Agent has not received notice from the Buyer that
a Stockholder has not satisfied the conditions set forth in Section 5.2 of the Merger Agreement, the Escrow Agent shall 

3

 

be
entitled to make distributions to said Stockholder as if said Stockholder has satisfied such conditions. Any portion of the Escrow Shares that are held by the Escrow Agent beyond the Escrow
Termination Date pursuant to the prior sentence shall be released by the Escrow Agent to the Stockholders or to the Buyer, as the case may be, only in accordance with Sections 3(a) and 3(b) above. 

         (d)   Notwithstanding anything to the contrary in this Agreement, if any number of Escrow Shares to be released at any time or under any
circumstances
exceeds the number of Escrow Shares then held by the Escrow Agent, the Escrow Agent shall release such number of shares then being held and shall have no liability or responsibility to the Escrow
Parties or the Stockholders for any deficiency, other than as a result of the bad faith, gross negligence or willful misconduct of the Escrow Agent. 

        4.    Reserved.    

        5.    Reserved.    

        6.    Rights, Responsibilities and Liability of Escrow Agent.    

        (a)   This Escrow Agreement sets forth, exclusively, the duties of the Escrow Agent and no additional duties or obligations shall be inferred
herefrom
or implied hereby. The Escrow Agent's duties shall be determined only with reference to this Agreement and applicable laws. The Escrow Agent is not charged with knowledge of or any duties or
responsibilities under any agreement or understanding to which the agency created hereby relates including, without limitation, the Merger Agreement. 

         (b)   Except in cases of the Escrow Agent's bad faith, willful misconduct or gross negligence, the Escrow Agent shall be fully protected
(i) in
acting in reliance upon any certificate, statement, request, notice, advice, instruction, direction, other agreement or instrument or signature reasonably and in good faith believed by the Escrow
Agent to be genuine, or (ii) in assuming that any person purporting to give the Escrow Agent any of the foregoing in accordance with the provisions hereof, or in connection with either this
Agreement or the Escrow Agent's duties hereunder, has been duly authorized to do so. The Escrow Agent shall not be liable for any mistake of fact or law or any error of judgment, or for any act or
omission, except as a result of its bad faith, willful misconduct or gross negligence. The Escrow Agent shall not be responsible for any loss incurred upon any investment made under circumstances not
constituting bad faith, willful misconduct or gross negligence. 

        In
connection with any payments that the Escrow Agent is instructed to make by wire transfer, the Escrow Agent shall not be liable for the acts or omissions of (i) any Escrow
Party or other person providing such instructions, including without limitation, errors as to the amount, bank information or bank account number, or (ii) any other person or entity, including
without limitation any Federal Reserve Bank, any transmission or communications facility, any funds transfer system, any receiver or receiving depository financial institution, and no such person or
entity shall be deemed to be an agent of the Escrow Agent. 

        Without
limiting the generality of the foregoing, it is hereby agreed that in no event will the Escrow Agent be liable for any lost profits or other indirect, special, incidental or
consequential damages that the parties may incur or experience by reason of having entered into or relied on this Agreement or arising out of or in connection with the Escrow Agent's services, even if
the Escrow Agent was advised or otherwise made aware of the possibility of such damages. In no event shall the Escrow Agent be liable for acts of God, breakdowns or malfunctions of machines or
computers, interruptions or malfunctions of communications or power supplies, labor difficulties, actions of public authorities, acts of war, or any other similar cause or catastrophe beyond the
Escrow Agent's reasonable control. 

4

 

         (c)   The Escrow Agent may consult with, and obtain advice from, legal counsel in the event of any dispute or question as to the construction
of any of
the provisions hereof or its duties hereunder, and it shall incur no liability and shall be fully protected in acting in good faith in accordance with the advice of such counsel. 

         (d)   The Escrow Agent shall not be bound by any modification of this Agreement unless it shall have specifically consented thereto in writing.

         (e)   Except as provided in Section 6(i) hereof, the Escrow Agent shall hold the Escrow Shares and provide the other services
described
in this Agreement in exchange for an annual account maintenance fee of $2,500.00 (the "Escrow Fees"), which amount shall be paid by the Buyer upon the
issuance by the Escrow Agent of an invoice for such amount. Except as provided in Section 6(i) hereof, neither the Company nor the Buyer shall have any obligation whatsoever to reimburse
the Escrow Agent, for any costs, fees or expenses including, without limitation, fees and expenses of counsel, which the Escrow Agent may incur in connection with the discharge of its duties hereunder
or the exercise of or enforcement by the parties of their respective rights hereunder. The Buyer agrees that the Escrow Agent shall be entitled to withhold any distribution to the Buyer otherwise
required to be made hereunder if any of the Escrow Fees owed to the Escrow Agent remain unpaid on the date such distribution would otherwise be made. 

        (f)    The Escrow Agent may resign by giving notice in writing to the Escrow Parties of such resignation, specifying a date when such
resignation shall
take effect (which shall in no event be earlier than twenty (20) business days after the giving of such notice). Thereafter, the Escrow Agent shall have no further obligation hereunder except
to hold the Escrow Shares. Promptly upon receipt of such notice, the Escrow Parties shall agree in writing upon a successor escrow agent who shall be mutually acceptable to them;  provided, that if the
Escrow Parties are unable to agree upon a successor escrow agent within ten (10) business days of receipt of such notice,
the Stockholder Representative and/or the Buyer may petition any court of competent jurisdiction for the appointment of such successor escrow agent or other appropriate relief and any such resulting
appointment shall be binding upon the parties hereto. Any such successor escrow agent shall deliver to each of the Escrow Parties, and to the Escrow Agent, a written instrument accepting such
appointment hereunder, and thereupon it shall succeed to all the rights and duties of the Escrow Agent hereunder, and shall be entitled to receive the Escrow Shares. The Escrow Agent shall deliver all
of the Escrow Shares to the successor escrow agent approved hereunder. 

        The
Escrow Parties acting together shall have the right to terminate the appointment of the Escrow Agent, specifying the date upon which such termination shall take effect. Thereafter,
the Escrow Agent shall have no further obligation to the Escrow Parties except to hold the Escrow Shares. In the event that the Escrow Parties exercise their right to terminate the appointment of the
Escrow Agent as aforesaid, the Escrow Parties agree that they will jointly appoint a banking corporation, trust company or attorney as successor escrow agent. The Escrow Agent shall refrain from
taking any action until it has received Joint Written Instructions from the Escrow Parties designating the successor escrow agent. The Escrow Agent shall deliver all of the Escrow Shares to such
successor escrow agent in accordance with such Joint Written Instructions and, upon receipt of the Escrow Shares, the successor escrow agent shall be bound by all of the provisions of this Agreement. 

        (g)   In the event of any dispute between the Escrow Parties, or between the Escrow Agent and any one or more of the other parties hereto, with
regard
to the Escrow Agent or its duties, or any other matter concerning the disposition of the Escrow Shares, or in the event that the Escrow Agent, in good faith, is in doubt as to what action it should
take hereunder, it may, without liability to any person, refrain from taking any action other than to keep safely the Escrow Shares until the Escrow Agent shall receive a Joint Written Instruction. 

5

  

         (h)   The parties hereto authorize the Escrow Agent, if the Escrow Agent is threatened with litigation or is sued in connection with this
Agreement,
or, at the Escrow Agent's option, in the event of a dispute or any good faith uncertainty in connection with this Agreement, to interplead all interested parties in any court of competent
jurisdiction. In the event of any dispute hereunder, the Escrow Agent shall be entitled to petition a court of competent jurisdiction for direction and shall perform any acts ordered by such court. 

         (i)    The Stockholders and the Buyer hereby agree to severally, but not jointly, indemnify the Escrow Agent for, and to hold it harmless
against, any
and all claims, suits, actions, proceedings, investigations, judgments, deficiencies, damages, settlements, liabilities and expenses (including reasonable legal fees and expenses of an attorney chosen
by the Escrow Agent) as and when incurred, arising out of or based upon any act, omission, alleged act or alleged omission by the Escrow Agent in connection with the acceptance of, or performance or
non-performance by the Escrow Agent of any of the Escrow Agent's duties under this Agreement, except as a result of the Escrow Agent's bad faith, willful misconduct or gross negligence. As
between the Stockholders and the Buyer, it is agreed that any such indemnification obligation shall be shared fifty percent (50%) by the Stockholders and fifty percent (50%) by the Buyer. In no event
shall any obligation to indemnify the Escrow Agent under this Section 6(i) be satisfied or partially satisfied by the Escrow Agent setting off or claiming against, or retaining or
attaching any of, the Escrow Shares, or by non-performance by the Escrow Agent of any of its duties hereunder; provided, that the parties
agree that the Escrow Agent shall be entitled to withhold any distribution otherwise required to be made of the Escrow Shares if any amounts owed to the Escrow Agent hereunder remain unpaid on the
date such distribution would otherwise be made. 

         (j)    Notwithstanding anything herein to the contrary, the provisions of Sections 6(b) and 6(i) hereof shall survive any resignation
or removal
of the Escrow Agent, and any termination of this Agreement. 

        7.    Customer Identification, Tax Withholding and Reporting.    To help the government fight the funding of terrorism
and money laundering activities, Federal law requires all financial institutions to obtain, verify and record information that identifies each individual or entity that opens an account. Therefore,
the Escrow Agent must obtain the name, address, taxpayer or other government identification number, and other information, such as date of birth for individuals, for each individual and business
entity that is a party to this Agreement. For individuals signing this Agreement, the Escrow Agent requires a copy of a driver's license, passport or other form of photo identification. The Escrow
Parties must provide the Escrow Agent with such documents as the Escrow Agent deems necessary to confirm the legal existence of each entity. 

        At
the time of or prior to execution of this Agreement, every individual executing this Agreement on behalf of an Escrow Party shall provide to the Escrow Agent a copy of a driver's
license, passport or other form of photo identification acceptable to the Escrow Agent. The Escrow Parties agree to provide to the Escrow Agent such organizational documents and documents establishing
the authority of any individual acting in a representative capacity as the Escrow Agent may require in order to comply with its established practices, procedures and policies. In the event that any
Escrow Party fails to provide any such organizational documents or documents establishing authority, or any individual executing this Agreement on behalf of an Escrow Party fails to provide to the
Escrow Agent an acceptable form of identification, within ten (10) days after the Escrow Agent requests the same, the Escrow Agent is authorized, notwithstanding any other provision of this
Agreement to the contrary, to retain the Escrow Shares until such documents are received by the Escrow Agent. 

        It
is understood that the Escrow Agent shall not be responsible for any information reporting with respect to income earned or dividends paid on the Escrow Shares, and is not responsible
for any other reporting. 

6

 

        8.    Reserved.    

        9.    Notices.    All notices, demands and communications to a part under this Agreement shall be in writing and shall
be deemed to have been duly given and received (a) if delivered personally, (b) three (3) business days after being mailed, certified mail, return receipt requested with postage
prepaid, (c) one (1) business day after being sent by nationally recognized overnight delivery service, with charges prepaid or (d) if sent via facsimile or similar electronic
transmission during normal business hours, (with a copy sent in the manner provided in clauses (a) or (b) above), as evidenced by mechanical confirmation of such fax or other electronic
transmission, to such party at its address set forth below (or such other address as it may from time to time designate in writing to the other parties hereto): 

	(i)	 	If to the Stockholder Representative, to:
	

 	
 	

Point Financial

30 S. 51st Street, Suite A-130

Phoenix, AZ 85044

Attention: Michael O'Malley

Telephone: (480) 785-1113

Facsimile: (480) 785-1117
	

 	
 	

with a copy (which shall not constitute notice) to:
	

 	
 	

Choate, Hall & Stewart LLP

Two International Place

Boston, MA 02110

Attn: William B. Asher, Jr.

Telephone: (617) 248-5000

Facsimile: (617) 248-4000
	

(ii)	
 	

If to the Buyer, to:
	

 	
 	

Advanced Cell Technology, Inc.

1201 Harbor Bay Parkway

Alameda, CA 94502

Attn: Jonathan Atzen

Telephone: (310) 481-5121

Facsimile: (310) 481-0833
	

 	
 	

with a copy (which shall not constitute notice) to:
	

 	
 	

Pierce Atwood LLP

One Monument Square

Portland, ME 04101

Attn: Christopher E. Howard

Telephone: (207) 791-1335

Facsimile: (207) 791-1350
	

(iii)	
 	

If to the Escrow Agent, to:
	

 	
 	

Mellon Trust of New England, N.A.

One Boston Place

Boston, Massachusetts 02108

Attn: Darci A. Buchanan or Matt Romero

Facsimile: (617) 248-3199
	 	 	 

7

 

	

 	
 	

with a copy (which shall not constitute notice) to:
	

 	
 	

Abendroth, Berns & Warner LLC

47 Church Street, Suite 301

Wellesley, Massachusetts 02482

Attn: Bruce D. Berns, Esq.

Facsimile: (781) 237-8891

        Any
party (and any other person designated to receive notice) may change its address for notice by delivery to all other parties of notice to such effect in the manner set forth herein. 

        10.    General.    

         (a)   Termination.    This Agreement and all the obligations of the Escrow
Agent hereunder
shall terminate upon the earliest to occur of (i) the release of the entirety of the Escrow Shares by the Escrow Agent; and (ii) the delivery of the entirety of the Escrow Shares by the
Escrow Agent in accordance with Section 6(f) hereof. 

         (b)   Survival.    Notwithstanding anything in this Agreement to the
contrary, the provisions
of Section 6 shall survive any resignation or removal of the Escrow Agent and any termination of this Agreement. 

         (c)   Entire Agreement.    This Agreement constitutes the entire agreement
with respect to
the subject matter hereof, and supersedes all other prior agreements and undertakings, both written and oral, among the parties, or any of them, with respect to the subject matter hereof and thereof. 

         (d)   Modifications; Waiver.    This Agreement may be amended, modified or
waived only by
written agreement of (i) the Company, (ii) the Buyer and (iii) the Escrow Agent. No course of conduct shall constitute a waiver of any terms or conditions of this Agreement,
unless such waiver is specified in writing, and then only to the extent so specified. A waiver of any of the terms and conditions of this Agreement on one occasion shall not constitute a waiver of the
other terms of this Agreement, or of such terms and conditions on any other occasion. 

         (e)   Further Assurances.    If at any time the Escrow Agent shall determine
or be advised
that any further agreements, assurances or other documents are reasonably necessary or desirable to carry out the provisions of this Agreement and the transactions contemplated by this Agreement, the
Escrow Parties shall execute and deliver any and all such agreements or other documents, and do all things reasonably necessary or appropriate to carry out fully the provisions of this Agreement. 

         (f)    No Third Party Beneficiaries; Assignment by Escrow Agent.    This Agreement is not
intended to confer upon any person other than the parties hereto any rights or remedies hereunder and shall not be assigned by any party by operation of law or otherwise;  provided, that upon prior
written notice to the Company and the Buyer, the Escrow Agent may assign this Agreement to an affiliated or successor trust
company or other qualified bank entity. 

        (g)   Section Headings.    The section headings contained in this Agreement
are inserted for
purposes of convenience of reference only and shall not affect the meaning or interpretation of this Agreement. 

         (h)   Governing Law.    This Agreement shall be governed by and construed in
accordance with
the laws of the Commonwealth of Massachusetts, without regard to principles of conflicts of law. 

        (i)    Counterparts and Electronic Execution.    This Agreement may be
executed in two or more
counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. The exchange of copies of this Agreement and of signature pages by
facsimile, e-mail or other similar electronic transmission shall constitute 

8

 

effective
execution and delivery of this Agreement as to the parties and may be used in lieu of the original Agreement for all purposes (and such signatures of the parties transmitted by facsimile,
email or other similar electronic communication shall be deemed to be their original signatures for all purposes). 

[The remainder of this page is intentionally left blank.] 

9

 

        IN
WITNESS WHEREOF, the parties have duly executed this Agreement, all as of the date first written above. 

	 	 	BUYER:
	

 	
 	

ADVANCED CELL TECHNOLOGY, INC.
	

 	
 	

By:	

 Name: William M. Caldwell, IV

Title: Chief Executive Officer
	

 	
 	
Stockholder Representative:
	

 	
 	

By:	

 Name: Michael O'Malley

Title: Stockholder Representative
	

 	
 	
Escrow Agent:
	

 	
 	
MELLON TRUST OF NEW ENGLAND, N.A.
	

 	
 	

By:	

	 	 	Name:	 
	 	 	Title:	 

10

 
EXHIBIT A

JOINT WRITTEN INSTRUCTIONS

FOR RELEASE FROM ESCROW SHARES  

        Pursuant to Section    of the Escrow Agreement, dated as of                , 2007, by
and among Advanced Cell Technology, Inc.,
a Delaware corporation (the "Buyer"), and Michael O'Malley (the "Stockholder Representative") and Mellon
Trust of New England, N.A., a national banking association, as escrow agent (the "Escrow Agent"), the Stockholder Representative and the Buyer hereby
instruct the Escrow Agent to release                        of the Escrow Shares in accordance with the following instructions:

Executed
by the undersigned as of this    day of                        , 200    . 

Buyer:  

        ADVANCED CELL TECHNOLOGY, INC.

	

By:	
 	

 Name:

Title:	
 	

 
	
Stockholder Representative:
 	
 	

 
	

By:	
 	

 Name: Michael O'Malley

Title: Stockholder Representative	
 	

 

11

QuickLinks

Exhibit 10.102Exhibit 10.110  

AMENDED AND RESTATED CONSULTING AGREEMENT  

        This Amended and Restated Consulting Agreement ("Agreement") is made and entered into as of the 19th day of September, 2007 (the "Effective Date"), by and between
Advanced Cell Technology, Inc., a Delaware corporation with offices located at 11100 Santa Monica Blvd, Suite 850, Los Angeles, CA 90025 ("ACT") through its wholly owned subsidiary
Mytogen, Inc., a Delaware corporation with offices located at 79/96 Thirteenth Street, Charlestown, MA 02129 ("Mytogen"), and Dib, LLC, an Arizona limited liability company with offices located
3951 East Paradise View Drive, Paradise Valley, AZ 85253. 

WITNESSETH:

        WHEREAS,
Nabil Dib ("Dib") and Mytogen previously entered into that certain Consulting Agreement dated as of January 1, 2006 (the "Original Consulting Agreement") pursuant to
which Dib provided services to Mytogen to assist Mytogen with the development of its myoblast product; and 

        WHEREAS,
the Original Consulting Agreement has been terminated; and 

        WHEREAS,
pursuant to that certain Agreement and Plan of Merger dated July 31, 2007, Mytogen has become a wholly owned subsidiary of ACT; and 

        WHEREAS,
Mytogen desires to continue its engagement of Dib to provide Mytogen certain services, including, without limitation, the development of Mytogen's myoblast product, including
phase 2 clinical trials related thereto; and 

        WHEREAS,
Dib desires to provide such services through Dib, LLC an Arizona limited liability company (Dib, LLC and its members, directors, officers, employees, representatives and agents
hereinafter referred to as "Consultant"); and 

        WHEREAS,
Mytogen and Consultant agree to have such services performed in accordance with the terms and conditions hereof of this Agreement, including the Statements of Work attached
hereto; and 

        WHEREAS,
Consultant and Mytogen are sometimes hereinafter referred to as the "parties". 

AGREEMENT  

        NOW THEREFORE, in consideration of the mutual covenants, agreements, representations, and warranties contained in this Agreement, and other good and valuable
consideration, the adequacy and receipt of which is hereby acknowledged, Mytogen and Consultant agree as follows: 

1.     TERMINATION OF ORIGINAL CONSULTING AGREEMENT; SERVICES  

        A.    Subject
to Sections 1.C and 1.D of this Agreement, the Original Consulting Agreement is hereby terminated by mutual agreement of the parties and all of its provisions are
hereby superceded and replaced by this Agreement. 

        B.    Subject
to the terms and conditions of this Agreement, Consultant agrees to perform the services and deliver the deliverables specified in the Statements of Work attached
hereto as Exhibit A (the "Myoblast Phase II Services"), Exhibit A-1 (the "Myoblast
Transplant Training Program Services"), Exhibit A-2 (the "Hemangioblast Research Services"), and  Exhibit A-3 (the "Saudi Arabia Initiative
Services"), as may be amended upon mutual written agreement of the parties (collectively, the
"Services"). The Statements of Work, each of which shall specifically refer to this Agreement and be signed by Consultant and a duly authorized representative of Mytogen, shall at a minimum include a
description of the services to be provided and deliverables to be delivered, and the time for performing and completing the services and delivering the deliverables. If there is any difference between
the terms 

1

 

and
conditions of any Statement of Work and the terms and conditions of this Agreement, the terms and conditions of this Agreement shall control. Consultant agrees to render the Services, and deliver
the deliverables (as identified or contemplated in Exhibits A, A-1, A-2 and A-3 and as further defined in Section 6 of this Agreement, the "Work
Product") in accordance with the schedules included in Exhibits A, A-1, A-2 and A-3. The parties agree, notwithstanding anything to the contrary in this
Agreement, that Mytogen and ACT shall conduct a quarterly review of the Services performed by Consultant. 

        C.    The
parties acknowledge and agree that it is the intent of the parties that the Myoblast Phase II Services and the Myoblast Transplant Training Program Services shall
commence upon the execution of this Agreement; and the Hemangioblast Research Services and the Saudi Arabian Initiative Services shall commence upon the completion of the Statements of Work for the
Hemangioblast Research Services and Saudi Arabian Initiative Services. The parties further acknowledge and agree that each Statement of Work, respectively, for the Myoblast Phase II Services, the
Myoblast Transplant Training Program Services, the Hemangioblast Research Services and the Saudi Arabian Initiative Services shall be completed and agreed upon by the parties in writing within thirty
days after the Effective Date. If all of the Statements of Work are not completed and agreed upon in writing by the parties within thirty (30) days following the Effective Date, this Agreement
shall immediately terminate and, notwithstanding anything to the contrary in this Agreement, the parties shall have no further obligations to each other after the date of such termination. 

        D.    Notwithstanding
any other provision of this Agreement, including without limitation Section 1.C above, Consultant acknowledges, understands and agrees that Dib
shall divest all equity interests in Mytogen and/or ACT held, directly or indirectly, by Dib, as Dib determines acceptable, within ninety (90) days of the Effective Date. If Dib is unable to
divest all equity interests in Mytogen and/or ACT held by Dib (whether directly or indirectly) within such ninety- (90) day period, as Consultant determines acceptable, this Agreement shall
terminate immediately and, notwithstanding anything to the contrary in this Agreement, the parties shall have no further obligations to each other after the date of such termination. 

2.     COVENANTS/WARRANTIES  

        A.    Consultant
represents that its member Dib has the requisite expertise, ability and legal right to perform and provide the Services. Dib shall perform the Services in a
timely, efficient and professional manner, consistent with industry standards. When on ACT's or Mytogen's premises Dib shall comply with ACT's and Mytogen's policies and procedures. Consultant shall
take such steps as reasonably necessary to prevent personal injury or property damage by its employees, agents or subcontractors in the course of performing Services hereunder. Consultant shall
indemnify, defend and hold harmless ACT and Mytogen from and against any loss, claim, liability or damages (including reasonable attorneys' fees) incurred by ACT or Mytogen arising out of or resulting
from, directly or indirectly, a breach by Consultant of any of the representations or warranties made by Dib under this Agreement or the gross negligence or willful misconduct of Consultant and/or its
members, employees, agents or subcontractors, except for any loss, claim, liability or damages (including reasonable attorneys' fees) caused by ACT's or Mytogen's (and/or ACT's or Mytogen's
shareholders, directors, officers, employees, agents or subcontractors) gross negligence, willful misconduct or fraud. ACT and Mytogen, jointly and severally, shall indemnify, defend and hold harmless
Consultant from and against any loss, claim, liability or damages (including reasonable attorneys' fees) incurred by Consultant arising out of or resulting from, directly or indirectly, a breach by
Mytogen or ACT of any of the representations or warranties made by Mytogen or ACT under this Agreement or the gross negligence or willful misconduct of Mytogen and/or ACT and/or its employees, agents
or subcontractors, except for any loss, claim, liability or damages (including reasonable attorneys' fees) caused,by Consultant's gross negligence, willful misconduct or fraud. 

2

 

        B.    Consultant
represents and warrants that (i) Consultant shall perform and provide the Services in accordance with all applicable laws, rules and regulations related
to the performance of the Services; (ii) the Work Product (defined in Section 6 herein) prepared for Mytogen under this Agreement does not, to Consultant's knowledge, infringe any
copyright, patent, trademark or any other proprietary right of any third party; (iii) Consultant is authorized to enter into this Agreement; (iv) Consultant is not under any obligation
to any person, firm, corporation or other entity ("Person") which conflicts with Consultant's obligations under this Agreement or would prevent, limit or impair in any material way the performance by
Consultant of Consultant's obligations hereunder; (v) subject to Section 1.D, Consultant has agreed that Dib will divest himself of any equity interest in Mytogen and/or ACT and shall
not hold any such interests during the performance of the Services under this Agreement; and (vi) Consultant agrees to maintain general liability insurance with a reputable insurance carrier
that is reasonably adequate to fulfill any potential obligation related to the Services provided hereunder, and Consultant agrees to continue to maintain such insurance during the term of this
Agreement and after the expiration or termination of this Agreement for a period of five (5) years. 

        C.    Notwithstanding
anything to the contrary in this Agreement, Mytogen and ACT acknowledge that they have received written notice of certain of Consultant's previous and/or
current professional involvements and relationships and Mytogen and ACT acknowledge and agree that such relationships and involvements (if any) shall not be deemed to violate this Agreement. Mytogen
and ACT acknowledge and agree that Consultant may engage in other businesses and investment activities in addition to those relating to Mytogen, subject to the terms and conditions of this Agreement,
including, without limitation, Section 7 below, and provided that Consultant shall not perform any services that interfere with Consultant's obligations under this Agreement (including any
Statement of Work). Neither Mytogen nor ACT shall have any right, by virtue of this Agreement or otherwise, to share or participate in such other permitted activities of Consultant or to the income or
proceeds derived therefrom. 

3.     INDEPENDENT PARTIES  

        Consultant is an independent contractor, and nothing contained in this Agreement shall be construed to make Consultant an employee, agent, partner or joint
venture of Mytogen, and Consultant shall not have the right to bind Mytogen to any agreement with a third party or to incur any obligation or liability on behalf of Mytogen. No fringe or employee
benefits are to be provided to Consultant by Mytogen. 

4.     COMPENSATION, EXPENSES AND BILLING  

        A.    In
full consideration for all Services to be rendered by Consultant hereunder and for the Work Product, Mytogen agrees to pay Consultant at the rates specified in  Exhibits A, A-1, A-2 and A-3.

        B.    All
fees to be paid to Consultant under paragraph (A) above (the "Fees") shall be invoiced by Consultant and paid by Mytogen as set forth in paragraphs 4(C) and
(D) below. 

        C.    Consultant
shall render to Mytogen an invoice on a monthly basis for Fees and any approved out-of-pocket expenses incurred since the date of the last invoice. Mytogen
reserves the right to request further verification of any out-of-pocket expenses as deemed appropriate under generally accepted accounting principles and Mytogen's internal policies. 

        D.    Mytogen
and/or ACT shall pay the undisputed portion of each invoice rendered in accordance with this Agreement within thirty (30) days of receipt thereof. 

5.     CONFIDENTIALITY AND PUBLICATIONS  

        A.    Consultant
acknowledges that prior to and during the term of this Agreement Consultant has had and will have access to confidential and proprietary information relating
to Mytogen's myoblast 

3

 

product,
Mytogen's hemangioblast product and Mytogen's cardio-myocyte program (if any) belonging to Mytogen ("Confidential Information"). Confidential Information shall include, but is not limited to,
any scientific, technical, trade or business information possessed, obtained by, developed for or given to Consultant relating to Mytogen's myoblast product, Mytogen's hemangioblast product and
Mytogen's cardio-myocyte program (if any) which is treated by Mytogen as confidential or proprietary including, without limitation, Work Product, research materials (including without limitation test
articles, test substances, medical devices, chemical compounds or other materials such as biologicals, including, without limitation, genes, DNA sequences, plasmids, vectors, expression systems,
cells, cell lines, organisms, antibodies, biological substances, and any constituents, progeny, mutants, derivatives or replications thereof or therefrom, together with all reagents, chemical
compounds or other materials), formulations, techniques, methodology, assay systems, formulae, procedures, tests, equipment, data, reports, know-how, sources of supply, patent positioning, patent
applications, relationships with consultants and employees, business plans and business developments, information concerning the existence, scope or activities of any research, development,
manufacturing, marketing or other projects of Mytogen relating to Mytogen's myoblast product, Mytogen's hemangioblast product and Mytogen's cardio-myocyte program (if any), all copies, digests,
summaries, extracts or the like of the Confidential Information, as well as feedback, suggestions, improvements or other inventions, ideas or works of authorship derived from the Confidential
Information, and any other confidential or proprietary information about or belonging to Mytogen's suppliers, licensors, licensees, partners, collaborators, affiliates, customers, potential customers
or others relating to Mytogen's myoblast product, Mytogen's hemangioblast product and Mytogen's cardio-myocyte program (if any). 

        B.    Notwithstanding
anything to the contrary in this Agreement, Confidential Information shall not include: (i) information that becomes generally available to third
parties through no fault or action of Consultant; (ii) information that Consultant has knowledge of prior to or after the Effective Date relating to the delivery or transport of cells and/or
genes, including, without limitation, the development and/or use of catheters and/or other devices, or anything else, except Confidential Information relating to Mytogen's myoblast product, Mytogen's
hemangioblast product and Mytogens' cardio-myocyte program (if any); and (iii) information that Consultant is required by a court or other governing body of competent jurisdiction to disclose;
provided, however, that Consultant shall advise Mytogen of any legal process or proceeding that could lead to the disclosure of Confidential Information so that Mytogen may seek appropriate legal
protection or relief, and Consultant shall reasonably cooperate with Mytogen in connection with Mytogen efforts to maintain the confidentiality of such Confidential Information). 

        C.    Consultant
acknowledges the interest to Mytogen in maintaining the confidential nature of the Confidential Information and, except as otherwise provided in this
Agreement, Consultant agrees that it will during the term of this Agreement and thereafter: (i) treat as confidential all Confidential Information; (ii) not use such Confidential
Information except as authorized herein or otherwise authorized in writing, (iii) implement reasonable procedures to prohibit the disclosure, unauthorized duplication, misuse or removal of the
Confidential Information; (iv) except as otherwise provided in Section 5.C(v), not disclose such Confidential Information to any third party, and (v) only disclose the
Confidential Information to those of its employees or agents who have need to know such Confidential Information in order to exercise the rights and fulfill the obligations set forth herein. Without
limiting the foregoing, Consultant shall protect the Confidential Information using at least the same procedures and degree of care that it uses to prevent the disclosure of its own confidential
information of like importance, but in no event less than reasonable care. Consultant agrees to insure that any employee or agent of Consultant who receives Confidential Information is bound by the
confidentiality obligations set forth in this Agreement. 

        D.    For
purposes of illustration, the Confidential Information may be contained in various media, including, without limitation, records of research data and observations,
records and results of preclinical trials and clinical trials, patent applications, regulatory filings, computer programs, manuals, 

4

 

plans,
drawings, designs, specifications, supply and customer lists, internal financial data and other documents and records, whether or not labeled or identified as "Confidential." 

        E.    All
Confidential Information is and shall remain the sole and exclusive property of Mytogen. Upon termination of this Agreement, Consultant shall deliver promptly to
Mytogen all Confidential Information belonging to Mytogen, together with all notes, summaries, memoranda, extracts or copies thereof, and Consultant shall not make, retain or distribute any copies
thereof. 

        F.     In
the event that Consultant wishes to make a publication (including any oral disclosure made without obligation of confidentiality) relating to work performed as part of
the Services, Consultant shall transmit to ACT a copy of the proposed written publication at least sixty (60) days prior to submission for publication, or an outline of such oral disclosure at
least thirty (30) days prior to presentation. ACT shall have the right (a) to propose modifications to the publication for patent or other reasons; and (b) to request a delay in
publication in order to protect patentable information. If ACT requests such a delay in writing, Consultant shall delay submission or presentation of the publication for a period of ninety
(90) days to enable patent applications protecting each party's rights in such information to be filed. If ACT reasonably claims that such information, whether or not patentable, may have
significant commercial value and can be maintained as a trade secret, Consultant shall publish or disclose only such information, which would not adversely affect such commercial value. Upon the
expiration of sixty (60) days or thirty (30) days from transmission to ACT, Consultant shall be free to proceed with the written publication or the presentation, respectively, unless ACT
has requested the delay in writing as described above. The parties expressly agree that research grant proposals submitted to governmental authorities or non-profit organizations shall not be subject
to review under this Section. The parties agree to abide by the policies of journals in which publications will appear as to such matters as the public release or availability of data or biological
materials relating to the publication. Authorship will be based on contributions to the proposed publication, in accordance with academic standards and custom. 

        G.    Consultant
agrees that monetary damages will not be sufficient to avoid or compensate for the unauthorized use or disclosure of any Confidential Information, and that
injunctive relief would be appropriate to prevent any such actual or threatened use or disclosure of such information. Mytogen shall be entitled to sue in equity and to enjoin any such breach, which
right shall be in addition to any and all other legal and equitable remedies to which Mytogen may be entitled to hereunder at law or in equity. 

        H.    Except
as otherwise provided in this Agreement, the rights and obligations of the parties under this Section 5 shall survive any expiration or termination of this
Agreement. 

6.     INTELLECTUAL PROPERTY AND OWNERSHIP RIGHTS  

        A.    Consultant
agrees that, except as otherwise expressly provided herein, any work product prepared for Mytogen hereunder in connection with the performance of the Services
as described in the Statements of Work, including without limitation, any research or preclinical or clinical trial results and data, or other tangible embodiments of such work, and any inventions,
improvements, concepts, or ideas made or conceived by Consultant in connection with and during the performance of such Services and related to the business of Mytogen (collectively, the "Work
Product") shall promptly be disclosed to and be the sole and exclusive property of Mytogen and shall be delivered to Mytogen. Any such Work Product that is eligible for copyright protection in the
United States or elsewhere is and shall be a "Work Made for Hire" as that phrase is defined by the U.S. copyright laws. If any Work Product is deemed for any reason not to be a Work Made for Hire,
Consultant agrees to and does hereby assign to Mytogen all of Consultant's right, title and interest in such Work Product, including, but not limited to, all copyrights, patents, trademarks, and other
proprietary rights, and all extensions and renewals thereof. Consultant agrees to waive all moral rights relating to the Work Product developed or 

5

 

produced,
including without limitation, any and all rights of identification of authorship and any and all rights of approval, restriction or limitation on use or subsequent modifications. 

        B.    Consultant
agrees to cooperate with ACT and Mytogen in the protection of any intellectual property rights that may derive as a result of the Services performed or Work
Product delivered by Consultant under the terms of this Agreement and/or as described in the Statement of Work. Consultant agrees to provide reasonable assistance and to execute, acknowledge and
deliver all documents reasonably requested by Mytogen in the establishment, publication, preservation, protection and enforcement of Mytogen's rights in such Work Product. 

        C.    Notwithstanding
anything to the contrary in this Agreement, the Parties acknowledge and agree that "Work Product" shall not include any of Consultant's work in the
development and/or use of catheters and/or other devices except as prepared specifically for Mytogen by Consultant solely in connection with Consultant's performance of the Services relating to
Mytogen's myoblast product, Mytogen's hemangioblast product and Mytogen's cardio-myocyte program (if any) as described in the Statements of Work; provided, however, that (a) Consultant shall
not be permitted to devote any time or resources toward the development and/or use of such catheters and/or devices for third parties in connection with or during the performance of the Services
required to be performed hereunder; (b) nothing in this Agreement shall be construed to be a license to, assignment of, transfer or permission to use of any of ACT's or Mytogen's materials
and/or intellectual property including, without limitation, any cells or cell lines developed or owned by ACT and/or Mytogen; and (c) nothing in this Agreement shall permit Consultant to
develop and/or use such catheters and/or devices with any third party that is a competitor of ACT or Mytogen. 

7.     NONCOMPETE AND NON-SOLICITATION  

        A.    Consultant
acknowledges that Dib is a key consultant of Mytogen and that Dib's talents and services are of a special, unique, unusual and extraordinary character and are
of particular and peculiar benefit and importance to Mytogen. Consultant further acknowledges that Mytogen will rely on Dib to conduct and engage in confidential research on innovative and proprietary
methods that relates to the Myoblast Phase II Services, including the myoblast product that Mytogen is developing, the Myoblast Transplant Training Program Services and the Hemangioblast Research
Services. In order for Mytogen to protect its interests against the competitive use of any Confidential Information, Work Product, knowledge or relationships concerning Mytogen and its business to
which Consultant will have access by virtue of the special nature of Consultant's relationship with Mytogen and its involvement in Mytogen's affairs, and in consideration of the payments made to
Consultant hereunder and the agreements of the parties herein, Consultant agrees that, except as otherwise provided in this Agreement, for so long as this Agreement is in effect and for a period of
one (1) year from the date of termination of Consultant's engagement with Mytogen, Consultant will not, without the express prior written consent of Mytogen, either directly or indirectly for
Consultant or for any other person, whether as a principal, agent or employee, owner, partner, director, shareholder or independent consultant or through any corporation, partnership, or other entity
(including without limitation, a sole proprietorship), solicit, divert or accept, any current or former customer of Mytogen or engage or participate in, assist in any manner or in any capacity or have
any interest in or make any loan to any Person engaged in the business of the development of cardiac myoblast treatment, a hemangioblast product and/or a cardio-myocyte program. Except as set forth in
Section 6 (c) above, ACT and Mytogen acknowledge and agree that Consultant's work in the development and/or use of catheters and/or other devices does not and shall not violate the terms
of this Section 7. During the same period, Consultant shall not hire or attempt to hire, for itself or on behalf of any other person or entity, any Mytogen employee or any person who was a
Mytogen employee at anytime during the period of Consultant's employment with the Mytogen. 

6

   
        B.    In recognition of the geographic extent of the Mytogen's existing and anticipated operations and the nature of the Mytogen's business and competitive circumstances, the
restrictive covenants contained herein shall apply worldwide. Consultant acknowledges, understands and agrees that the restrictions in this Section 7 are necessary and reasonable to protect
Mytogen's business. 

8.     LIMITATION OF LIABILITY  

        Except for any liability under Section 2 (Indemnification) or 5 (Confidentiality), in no event shall Mytogen or Consultant be liable for any incidental,
consequential, or punitive damages as a result of their performance or breach of this Agreement, whether or not the possibility of such damages has been disclosed to the other party. 

9.     TERM  

        This Agreement shall commence of the Effective Date and continue in full force and effect until the earlier of (i) termination in accordance with
Section 10 of this Agreement, or (ii) completion of the Services. 

10.   TERMINATION  

        A.    Consultant's
engagement under this Agreement shall be terminated upon the earliest to occur of any of the following: 

	(i)
	the
death of the Consultant;

	(ii)
	Consultant's
inability to perform its duties on account of disability or incapacity of Dib for a period of six (6) or more months, as determined by Mytogen's
President.

	(iii)
	written
notice to Consultant that Mytogen is terminating Consultant's engagement hereunder without cause.

	(iv)
	the
termination of Consultant's engagement by Consultant at any time without Good Reason (as defined below).

	(v)
	the
termination of Consultant's engagement by Consultant at any time for Good Reason. For purposes of this Agreement, "Good Reason" shall mean (1) a breach by
Mytogen and/or ACT of any material provision of this Agreement if Mytogen and/or ACT fails to cure said breach within thirty (30) days after written notice thereof; (2) the termination
of the Statement of Work relating to the Myoblast Transplant Training Services and/or the Myoblast Phase II Services or (3) a requirement that Consultant relocate to somewhere other than
Maricopa County, Arizona.

	(vi)
	the
termination of Consultant's engagement by ACT or Mytogen at any time "for cause," such termination to take effect immediately upon written notice from ACT or
Mytogen to Consultant. The term "for cause" means a determination by ACT or Mytogen that Consultant (1) refused to obey lawful written orders of the Chief Executive Officer or Chief Development
Officer of ACT or Mytogen if Consultant fails to cure such refusal within thirty (30) days after written notice thereof; (2) breached or neglected its duties or obligations or any
material provision under this Agreement, if Consultant fails to cure such breach or neglect within thirty (30) days after written notice thereof; (3) committed any act involving
disloyalty, dishonesty, fraud or any other act resulting in a conviction of Consultant of a crime; (4) wilfully caused an act or omission to occur that caused the Myoblast Phase II program and
the Myoblast Phase II Services to be placed on "clinical hold" by the FDA and such act or omission is not cured within a period of ninety (90) days; (5) the commission of any act which
constitutes a violation of a material policy of ACT or Mytogen that has or has the potential to negatively impact 

7

 

ACT,
Mytogen or any of the clinical programs for which Consultant performs Services, if Consultant fails to cure such violation within thirty (30) days after written notice therof (if
possible); or (6) conviction of or a plea of guilty or "no contest" to any felony or a crime involving moral turpitude. Except as provided under Section 10.C below, upon such termination
for cause under this subsection (vi), the only obligation Mytogen will have under this Agreement will be to pay Consultant's unpaid Fee accrued through the date of termination. 

	(vii)
	the
termination of Consultant's engagement by ACT or Mytogen for any reason within six months of a Change in Control of ACT and/or Mytogen. A "Change in Control"
(a) a liquidation of assets or a sale of all or substantially all of ACT's and/or Mytogen's assets to an unrelated party in a single transaction or series of related transactions;
(b) any merger, consolidation, sale of stock or other transaction (or series of related transactions) that results in any "person" or "group" (each as used in Sections 13(d)(3) and 14(d)(2) of
the Exchange Act) becoming the beneficial owner (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of voting securities of the ACT and/or Mytogen (or securities converted
into or exchangeable for such voting securities) representing fifty percent (50%) or more of the combined voting power of all voting securities of ACT and/or Mytogen (on a fully diluted basis) where
such person or group did not beneficially own, directly or indirectly, such voting power prior to consummation of such transaction; or (c) any other event that results, by contract or
otherwise, in such person or group obtaining the ability, directly or indirectly, to elect a majority of ACT's and/or Mytogen's Board of Directors of or otherwise direct the management and policies of
ACT and/or Mytogen. 

        B.    Subject
to Section 10.A(v), Mytogen may terminate any other Statement of Work under this Agreement (but less than all Statements of Work, which would be governed
by Section 10.A(iii) above) for any reason at any time upon thirty (30) days written notice to Consultant. In the event Mytogen terminates less than all of the Statements of Work,
this Agreement shall continue in force with respect to the remaining Statements of Work. 

        C.    Upon
the termination of this Agreement pursuant to clauses (iii) or (v) only of Section 10.A, Consultant shall be entitled to receive as a severance
payment an amount equal to One Hundred Seventy-Five Thousand Dollars ($175,000.00), payable in a lump sum within ten (10) business days of the effective date of such termination. Upon the
termination of this Agreement pursuant to clause (vii) only of Section 10.A, Consultant shall be entitled to receive as a severance payment an amount equal to fifty percent (50%) of the
annual compensation pursuant to any Statement of Work in effect of the date of the Change in Control, payable in a lump sum within ten (10) business days of the effective date of such
termination. 

        D.    Upon
the termination of Consultant's engagement for any reason, by either party, the Consultant shall immediately return to Mytogen any property of Mytogen in its
possession; return of this property shall be a precondition to the payment of any further compensation owed by Mytogen to the Consultant, if any, pursuant to Section 10.C. 

        E.    Termination
of this Agreement pursuant to this Section 10 shall not affect rights and obligations accruing prior to the date of termination, including without
limitation with respect or relating to the parties' respective obligations under Sections 2, 5 and 6 hereof. Except as otherwise provided in this Agreement, in the event of termination of this
Agreement Mytogen shall have no further obligations hereunder other than amounts owed for Services actually performed and not in dispute and invoiced in accordance with this Agreement prior to the
date of such termination. Upon the termination of this Agreement pursuant to Section 1.C or Section 1.D or clauses (iii), (v) and/or (vii) of Section 10.A,
Consultant shall have no further obligations hereunder to Mytogen and/or ACT, 

8

 

including,
without limitation, with respect to or relating to the non-compete and non-solicitation covenants set forth in Section 7 of this Agreement. 

11.   NOTICES  

        Any notice, payment or other communication required under this Agreement shall be deemed given (i) if by hand delivery, upon receipt thereof,
(ii) if mailed, five (5) days after deposit in the United States mail, postage prepaid, certified mail return receipt requested, (iii) if by facsimile transmission, upon
electronic confirmation thereof, or (iv) if by next day delivery service, upon such delivery. All notices shall be sent to the address of the party set forth above (or such other address as
either party may in the future specify in writing to the other). 

12.   NON-ASSIGNABILITY  

        This Agreement is personal to Consultant. Consultant may not assign or transfer any of the rights, duties or obligations herein, without the prior written consent
of Mytogen, provided that Consultant may assign this Agreement to an entity which is solely owned by Consultant without the prior written consent of Mytogen, and provided further that all Services
provided hereunder must continue to be performed by Dib following such assignment or transfer to such entity. 

13.   GOVERNING LAW  

        This Agreement shall be governed by and construed and interpreted in accordance with the laws of the Commonwealth of Massachusetts, without regard to principles
of conflicts of law thereof. 

14.   ARBITRATION  

        A.    Confidential Arbitration.    If any dispute shall arise between ACT, Mytogen and/or Consultant in connection
with this Agreement, ACT, Mytogen and/or Consultant may serve upon others a written notice demanding that such dispute be resolved by confidential arbitration; provided, however, if the controversy
requires provisional remedies, such as injunctive relief or attachment, ACT, Mytogen and/or Consultant may elect to have the matter determined by a court of competent jurisdiction. Unless ACT, Mytogen
and/or Consultant elect otherwise, any such arbitration shall be conducted under the commercial arbitration rules of the American Arbitration Association. Any arbitration proceeding shall take place
in Boston, Massachusetts. The award of the arbitrator shall be final, binding and enforceable in any court of competent jurisdiction. If it is necessary for ACT, Mytogen and/or Consultant to enforce
the award of the arbitrator in any court proceeding, such Person(s) shall be entitled to all attorneys' fees and costs associated with such proceeding as well as all of its costs associated with the
arbitration hearing. 

        B.    Proceeding Expenses.    In any controversy, claim or dispute arising out of, or relating to, this Agreement or
the method and manner of performance hereof, the prevailing party, as determined by the arbitrator or court, as applicable, shall be entitled to and shall be awarded, in addition to any other relief,
proceeding expenses. If no party wholly prevails, the party that substantially prevails, as determined by the arbitrator or court, shall be awarded proceeding expenses. In determining the award of
proceeding expenses, attorneys' fees, proceeding costs, cost of investigation and other reasonable expenses shall be included. For the purposes of this provision, the term "proceeding" shall include
arbitration, administrative, bankruptcy and judicial proceedings, including appeals therefrom. 

15.   WAIVER  

        The waiver by either party of any breach of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach of any
provision of this Agreement. 

9

 

16.   ENTIRE AGREEMENT  

        This Agreement and any exhibits and schedules attached hereto (which are incorporated into this Agreement by this reference) sets forth the entire understanding
between the parties relating to the subject matter hereof and supersedes any previous understandings or agreements, written or oral, between Consultant and Mytogen. This Agreement may be modified only
by an agreement in writing signed by both parties. 

17.   AGREEMENT BINDING ON SUCCESSORS  

        This Agreement shall inure to the benefit of and be binding upon Mytogen's and Consultant's respective successors, executors, administrators, heirs and/or
permitted assigns. 

18.   SEVERABILITY  

        If any provision or portion of this Agreement is held to be unenforceable or invalid, the remaining provisions and portions shall nevertheless be given full force
and effect, and the parties agree to negotiate, in good faith, a substitute valid provision which most nearly effects the parties' intent in entering this Agreement. 

19.   HEADINGS  

        The headings to the various Sections and paragraphs of this Agreement have been inserted for convenient reference only, and shall not to any extent have the
effect of modifying, amending or changing the express terms and provisions of this Agreement. 

20.   COUNTERPARTS  

        This Agreement may be executed by facsimile and in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. 

[The
signature page is the next page.] 

10

 

        IN
WITNESS WHEREOF, the parties hereto have caused this Amended and Restated Consulting Agreement to be duly executed under seal and delivered as of the Effective Date. 

	 	 	MYTOGEN, INC.
	

 	
 	

By:	
 	

/s/  WILLIAM M. CALDWELL, IV      

	 	 	Printed Name: William M. Caldwell, IV

Title: Chief Executive Officer
	

 	
 	
DIB, LLC
	

 	
 	

By:	
 	

/s/  NABIL DIB, M.D.      

	 	 	Printed Name: Nabil Dib, M.D.

Title: Managing Member
	

ADVANCED CELL TECHNOLOGY, INC.

hereby acknowledges the terms and conditions of this Agreement and consents to terms of the Agreement applicable to it	
 	

 	
 	

 

 

	By:	 	/s/  WILLIAM M. CALDWELL, IV      
	 	 
	Printed Name: William M. Caldwell, IV

Its: Chief Executive Officer	 	 

11

   EXHIBIT A  

STATEMENT OF WORK

for

MYOBLAST PHASE II SERVICES  

[Provide
detailed description of services and fees to be paid—fees shall include a commercially reasonable premium above standard procedural charge] 

12

   EXHIBIT A-1  

STATEMENT OF WORK

for

MYOBLAST TRANSPLANT TRAINING PROGRAM SERVICES  

[Provide
detailed description of services and fees [$350,000 per year] to be paid] 

13

   EXHIBIT A-2  

STATEMENT OF WORK

for

HEMANGIOBLAST RESEARCH SERVICES  

[Provide
detailed description of services and fees [$100,000 per year] to be paid] 

14

   EXHIBIT A-3  

STATEMENT OF WORK

for

SAUDI ARABIA INITIATIVE SERVICES  

[Provide
detailed description of services and fees [$150,000 initial fee] to be paid] 

15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}]]